BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 28096054)

  • 1. Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-α activity restored are at risk of developing hepatic tumors.
    Kim GY; Lee YM; Kwon JH; Cho JH; Pan CJ; Starost MF; Mansfield BC; Chou JY
    Mol Genet Metab; 2017 Mar; 120(3):229-234. PubMed ID: 28096054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene therapy prevents hepatic tumor initiation in murine glycogen storage disease type Ia at the tumor-developing stage.
    Cho JH; Lee YM; Starost MF; Mansfield BC; Chou JY
    J Inherit Metab Dis; 2019 May; 42(3):459-469. PubMed ID: 30637773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy.
    Lee YM; Jun HS; Pan CJ; Lin SR; Wilson LH; Mansfield BC; Chou JY
    Hepatology; 2012 Nov; 56(5):1719-29. PubMed ID: 22422504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy using a novel G6PC-S298C variant enhances the long-term efficacy for treating glycogen storage disease type Ia.
    Zhang L; Lee C; Arnaoutova I; Anduaga J; Starost MF; Mansfield BC; Chou JY
    Biochem Biophys Res Commun; 2020 Jun; 527(3):824-830. PubMed ID: 32430177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evolutionary approach to optimizing glucose-6-phosphatase-α enzymatic activity for gene therapy of glycogen storage disease type Ia.
    Zhang L; Cho JH; Arnaoutova I; Mansfield BC; Chou JY
    J Inherit Metab Dis; 2019 May; 42(3):470-479. PubMed ID: 30714174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging roles of autophagy in hepatic tumorigenesis and therapeutic strategies in glycogen storage disease type Ia: A review.
    Cho JH; Weinstein DA; Lee YM
    J Inherit Metab Dis; 2021 Jan; 44(1):118-128. PubMed ID: 32474930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal hepatic glucose-6-phosphatase-α activity required to sustain survival and prevent hepatocellular adenoma formation in murine glycogen storage disease type Ia.
    Lee YM; Kim GY; Pan CJ; Mansfield BC; Chou JY
    Mol Genet Metab Rep; 2015 Jun; 3():28-32. PubMed ID: 26937391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mice expressing reduced levels of hepatic glucose-6-phosphatase-α activity do not develop age-related insulin resistance or obesity.
    Kim GY; Lee YM; Cho JH; Pan CJ; Jun HS; Springer DA; Mansfield BC; Chou JY
    Hum Mol Genet; 2015 Sep; 24(18):5115-25. PubMed ID: 26089201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia.
    Lee YM; Pan CJ; Koeberl DD; Mansfield BC; Chou JY
    Mol Genet Metab; 2013 Nov; 110(3):275-80. PubMed ID: 23856420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete normalization of hepatic G6PC deficiency in murine glycogen storage disease type Ia using gene therapy.
    Yiu WH; Lee YM; Peng WT; Pan CJ; Mead PA; Mansfield BC; Chou JY
    Mol Ther; 2010 Jun; 18(6):1076-84. PubMed ID: 20389290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver-directed gene therapy for murine glycogen storage disease type Ib.
    Kwon JH; Lee YM; Cho JH; Kim GY; Anduaga J; Starost MF; Mansfield BC; Chou JY
    Hum Mol Genet; 2017 Nov; 26(22):4395-4405. PubMed ID: 28973635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic lentiviral gene transfer prevents the long-term onset of hepatic tumours of glycogen storage disease type 1a in mice.
    Clar J; Mutel E; Gri B; Creneguy A; Stefanutti A; Gaillard S; Ferry N; Beuf O; Mithieux G; Nguyen TH; Rajas F
    Hum Mol Genet; 2015 Apr; 24(8):2287-96. PubMed ID: 25561689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction of metabolic abnormalities in a mouse model of glycogen storage disease type Ia by CRISPR/Cas9-based gene editing.
    Arnaoutova I; Zhang L; Chen HD; Mansfield BC; Chou JY
    Mol Ther; 2021 Apr; 29(4):1602-1610. PubMed ID: 33359667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer.
    Ghosh A; Allamarvdasht M; Pan CJ; Sun MS; Mansfield BC; Byrne BJ; Chou JY
    Gene Ther; 2006 Feb; 13(4):321-9. PubMed ID: 16195703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic glucose-6-phosphatase-α deficiency leads to metabolic reprogramming in glycogen storage disease type Ia.
    Cho JH; Kim GY; Mansfield BC; Chou JY
    Biochem Biophys Res Commun; 2018 Apr; 498(4):925-931. PubMed ID: 29545180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of pathways implicated in liver inflammation and tumorigenesis of glycogen storage disease type Ia mice receiving gene therapy.
    Kim GY; Kwon JH; Cho JH; Zhang L; Mansfield BC; Chou JY
    Hum Mol Genet; 2017 May; 26(10):1890-1899. PubMed ID: 28334808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term complications of glycogen storage disease type Ia in the canine model treated with gene replacement therapy.
    Brooks ED; Landau DJ; Everitt JI; Brown TT; Grady KM; Waskowicz L; Bass CR; D'Angelo J; Asfaw YG; Williams K; Kishnani PS; Koeberl DD
    J Inherit Metab Dis; 2018 Nov; 41(6):965-976. PubMed ID: 30043186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia.
    Koeberl DD; Pinto C; Sun B; Li S; Kozink DM; Benjamin DK; Demaster AK; Kruse MA; Vaughn V; Hillman S; Bird A; Jackson M; Brown T; Kishnani PS; Chen YT
    Mol Ther; 2008 Apr; 16(4):665-72. PubMed ID: 18362924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of tumor-promoting pathways implicated in hepatocellular adenoma/carcinoma, a long-term complication of glycogen storage disease type Ia.
    Cho JH; Lee YM; Bae SH; Chou JY
    Biochem Biophys Res Commun; 2020 Jan; 522(1):1-7. PubMed ID: 31735334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia.
    Gjorgjieva M; Calderaro J; Monteillet L; Silva M; Raffin M; Brevet M; Romestaing C; Roussel D; Zucman-Rossi J; Mithieux G; Rajas F
    J Hepatol; 2018 Nov; 69(5):1074-1087. PubMed ID: 30193922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.